Opendata, web and dolomites

AURORAX SIGNED

Advancing cancer detection through metabolism-based diagnostics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 AURORAX project word cloud

Explore the words cloud of the AURORAX project. It provides you a very rough idea of what is the project "AURORAX" about.

risk    20    platform    too    metastatic    improves    signature    multiple    rcc    algorithmic    competition    metabolism    off    rates    oncologist    scalable    basis    niche    detect    clearance    cancer    introduce    indications    optimize    sweden    receive    patients    terminal    former    treatment    letters    carcinoma    ruo    ing    139    laboratories    easily    pharmaceutical    detected    regulatory    small    risks    disease    frequency    starting    companies    sales    sensitivity    perform    first    benefit    imaging    diagnostics    frequent    significantly    generate    market    200b    effectiveness    surgery    demonstrated    business    expressing    patient    drop    validation    monitoring    urine    blood    launch    renal    obtain    surveil    ups    radiation    stage    follow    enter    aur87    quantification    strategy    stages    clinical    annual    elypta    outcomes    survival    metabolite    letter    trial    recurrences    urologists    diagnosed    12    cell    regular    exceptional    financially    limited    liquid    signed    trials    independent    biopsy    solid    aurorax    recurrence    once   

Project "AURORAX" data sheet

The following table provides information about the project.

Coordinator
ELYPTA AB 

Organization address
address: REGERINGSGATAN 65, 3TR
city: STOCKHOLM
postcode: 111 56
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Total cost 3˙346˙674 €
 EC max contribution 2˙342˙671 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2021-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ELYPTA AB SE (STOCKHOLM) coordinator 2˙342˙671.00

Map

 Project objective

Former cancer patients receive regular follow-ups to detect recurrences at early stages and optimize treatment outcomes. The follow-up frequency is currently limited by costs and radiation risks of imaging approaches used to surveil for recurrences, resulting in recurrences being detected too late – often resulting in terminal disease. Of the 139.000 annual Renal Cell Carcinoma (RCC) patients, 20% are diagnosed with a metastatic recurrence within 5 years after surgery. Once metastatic, RCC survival rates drop to 12% over 5 years survival. Elypta, Sweden, has developed the first metabolism-based liquid biopsy to detect early-stage recurrences. The quantification of a metabolite signature in blood or urine and an algorithmic analysis allows for exceptional sensitivity, a low cost of the platform and significantly improves on imaging approaches in cost and risk, enabling frequent patient follow-up. Elypta’s technology has been demonstrated in small clinical trials and its cost effectiveness assessed by two independent companies. Elypta’s platform is easily scalable to other cancer indications and applications such as treatment monitoring, as demonstrated in multiple small trials. Starting in the niche RCC market with limited competition, Elypta now requires clinical evidence for a product launch within RCC. The business strategy focuses on distribution and sales through clinical laboratories, which will benefit financially off sales. During the AURORAX, Elypta will 1) perform a clinical validation trial (AUR87) to generate strong clinical evidence, 2) obtain regulatory clearance in the EU and the US and 3) introduce the product for research use only (RUO) and after clinical validation enter the RCC diagnostics market in EU. As users of the platform, oncologist and urologists have all signed letters of support. A pharmaceutical partner has also signed a letter of support, expressing their interest in RUO use of the platform, providing a solid basis in the emerging liquid biopsy market (€200B market).

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "AURORAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "AURORAX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

HUD (2018)

COMMERCIALIZING THE FIRST HEAD-UP-DISPLAY FOR OFF-HIGHWAY VEHICLES

Read More  

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

Presque (2019)

Smart Nursing Bra

Read More